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Market Suspension of Aprotinin (Trasylol®)
due to Potential Safety Concerns
On November 5, 2007, FDA announced the marketing suspension of aprotinin (Trasylol®) by
Bayer Pharmaceutical Corporation. This suspension was at the
request of FDA pending a detailed review of preliminary results from a Canadian study that
suggested an increased risk for
death associated with aprotinin
compared with other agents.
Aprotinin is indicated for prophylactic use to reduce perioperative blood loss and the
need for blood transfusion in patients undergoing cardiopulmonary bypass in the course of coronary artery bypass graft surgery. It has been on the market
since the early 1990s and has
been used widely during cardiothoracic surgery in both adult
and pediatric patients.
On October 19, 2007, FDA was
notified that the Data and Safety
Monitoring Board (DSMB) recommended to stop patient enrollment in the aprotinin treatment
group in the BART (Blood conservation using antifibrinolytics:
A randomized trial in a cardiac
surgery population) study. The
preliminary findings suggested
that aprotinin increases the risk

of death when compared with the
antifibrinolytic drugs, aminocaproic acid and tranexamic acid.
The BART study was designed to
show that aprotinin was superior
to aminocaproic acid and tranexamic acid in decreasing the occurrence of massive bleeding associated with cardiac surgery. The
study had planned to enroll approximately 3,000 adult patients
who were to undergo various
types of cardiac surgery that
placed them at high risk for bleeding.
Information from the interim
analyses performed by the DSMB
is limited, but the following was
sent to FDA:
▪ the 30-day mortality in the
aprotinin group nearly had
reached conventional statistical
significance at the interim analysis when compared with the
other agents;
▪ a trend toward increased mortality in the aprotinin group had
been observed throughout the
study;
▪ the use of aprotinin was associated with less serious bleeding
than the other agents; however,
more deaths due to hemorrhage
had been observed among patients receiving aprotinin;

Page 2

▪ the DSMB concluded that continued enrollment of patients
into the aprotinin group was
unlikely to significantly change
the study findings.
FDA determined that these preliminary data support the findings
from observational studies that
also suggested increased risks for
mortality when aprotinin was
compared to other antifibrinolytic
drugs. FDA will work will the
study sponsor to fully evaluate the
data and determine the risk and
benefits of aprotinin. This may
lead to additional labeling or other
regulatory action. During the review period, FDA recommends
that health care providers review
the risks and benefits of aprotinin
outlined in the label and in the information provided by the manufacturer and discuss the information with their patients.
There are limited treatment options for patients at risk for exces-
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sive bleeding during cardiac surgery. Therefore, FDA is working
with Bayer to phase aprotinin
out of the marketplace in a way
that does not cause shortages of
other drugs used for this purpose. Until FDA can review the
data from the terminated study it
is not possible to determine and
identify a population of patients
undergoing cardiac surgery for
which the benefits of aprotinin
outweigh the risks. Understanding that individual doctors may
identify specific cases where
benefit outweighs risk, FDA is
exploring ways for physicians to
have continued but limited access to aprotinin.
After reviewing the literature
regarding alternatives, there is
limited literature to support aminocaproic acid and tranexamic
acid in certain patients at high
risk for bleeding. Therefore, after consultation with the Department of Anesthesiology and the

Figure 1. Clinical Guidelines for Aprotinin (Trasylol®)
Due to the current marketing suspension for aprotinin by the Food and Drug
Administration and the manufacturer, Bayer, the use of aprotinin has been restricted to the following clinical indications:
For adult patients, aprotinin is approved for the following:
▪ Complex aortic surgery requiring profound hypothermic circulatory arrest
▪ Explantation of a mechanical assist device for cardiac recovery or
heart transplantation
▪ Redo sternotomy for cardiac transplantation
▪ Redo sternotomy for endocarditits
▪ Any cardiac procedure performed on a patient who has received clopidogrel within
3 to 5 days prior to surgery
For pediatric patients, aprotinin is approved for the following:
▪ Open-heart cases for neonates (patients less than 1 month of age)
▪ Complex re-operative surgery (ie, third time or greater "re-do's," patients on ECMO
or a ventricular assist device at the time of surgery)
If a patient does not meet one of the indications stated above, approval for
aprotinin use must be obtained by an attending physician from the Chair or
Secretary of the Pharmacy and Therapeutics Committee per policy C-82.

Division of Cardiothoracic Surgery, the Pharmacy and Therapeutics Committee has maintained
aprotinin on the MUSC-MC Formulary of Accepted with use restricted by prescribing service (ie,
Anesthesiology, Pediatric Cardiothoracic Surgery, Adult Cardiothoracic Surgery) AND per the
clinical criteria listed in Figure 1.
The guidelines are posted on the
Formulary and Drug Information
Resources page under Medication
Use Policies/Guidelines.
FDA and Bayer will be working
together to create a program during the temporary suspension under which physicians in these markets might request and receive
aprotinin for treatment of certain
surgical patients with an established medical need. The company
will work with the FDA, Health
Canada, and any other authorities
who wish to institute similar programs, to outline appropriate patient profiles and the specific details. Until the FDA and manufacturer develop a process for distribution, aprotinin use will be determined by availability from the distributor. Once current stock is
depleted, it will be unavailable for
use.

Strengthened Boxed
Warnings for
ErythropoiesisStimulating Agents
FDA approved revised boxed
warnings and other safety-related
product labeling changes for
erythropoiesis-stimulating agents
(ESAs) [epoetin alfa (Procrit®,
Epogen®), darpoetin (Aranesp®).]
These agents are approved for the
treatment of anemia in patients
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with chronic kidney failure and
anemia caused by chemotherapy
in certain patients with cancer.
Epoetin alfa products are also approved for use in certain patients
with anemia who are scheduled to
undergo major surgery to reduce
blood transfusions during or
shortly after surgery and for the
treatment of anemia caused by
zidovudine therapy in HIV
patients.
The revised statements address the
risks that ESAs pose to patients
with cancer and patients with
chronic kidney failure. The labeling changes, which incorporate
advice from FDA advisory committees and expand upon labeling
changes made in March 2007, also
include a statement that symptoms
of anemia, fatigue, and quality of
life have not been shown to improve in patients with cancer who
are treated with ESAs.
For patients with cancer, the new
boxed warnings emphasize that
ESAs caused tumor growth and
shortened survival in patients with
advanced breast, head and neck,
lymphoid and non-small cell lung
cancer when they received a dose
that attempted to achieve a hemoglobin concentration of 12 g/dL or
greater. The warnings also emphasize that no clinical data are
available to determine whether
there is a similar risk of shortened
survival or increased tumor
growth for patients with cancer
who receive an ESA dose that attempts to achieve a hemoglobin
concentration of less than 12 g/dL.
An earlier boxed warning, approved in March 2007, described
the results of 6 studies demon-
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strating that survival was shorter
and time to tumors progression
was faster when ESAs were used
to achieve hemoglobin concentrations above 12 g/dL in cancer
patients. The current warning
clarifies that ESAs should only
be used in patients with cancer
when treating anemia specifically caused by chemotherapy
and not for other causes of anemia. Additionally, it states that
ESAs should be discontinued
once the patient's chemotherapy
course has been completed.

demonstrated similar results to the
previous 6 studies reviewed by the
agency. When taken together, all
8 studies show more rapid tumor
growth or shortened survival in
patients with breast, non-small
cell lung, head and neck, lymphoid, or cervical cancers who
received ESAs compared with patients who did not receive treatment. All in patients receiving
ESAs, the goal hemoglobin was
greater than 12 g/dL, although
many patients did not reach that
level.

For patients with chronic kidney
failure, the new warning states
that ESAs should be used to
maintain a hemoglobin concentration between 10 and 12 g/dL.
Maintaining higher hemoglobin
concentrations in patients with
chronic kidney failure increases
the risk for death and for serious
cardiovascular reactions such as
stroke, heart attack, or heart failure. Additionally, the new labeling provides specific instructions
for dosage adjustments and hemoglobin monitoring for chronic
kidney failure patients who do
not respond to ESA treatment
with an adequate increase in
their hemoglobin concentrations.

FDA will continue to analyze data
and do plan to revisit the risk and
benefits at a public advisory meeting in the near future.

The new labeling also emphasizes that there are no data from
controlled trials demonstrating
that ESAs improve symptoms of
anemia, quality of life, fatigue,
or patient well-being for patients
with cancer or for patients with
HIV undergoing AZT therapy.
Early this month, FDA issued
another statement regarding the
safety of ESAs. An additional 2
studies were reviewed, which

The current labeling for both
ESAs is included in Table 1. It is
important that health care professional follow the labeling set forth
by the FDA and to monitor patients very closely for increases in
hemoglobin greater than 12 g/dL.
For more information, see the
FDA communication at the following URL:
www.fda.gov/cder/drug/early_comm/ESA.htm.

Direct Thrombin
Inhibitor (DTI)
Preprinted Order
Form and Protocol
At the November Pharmacy and
Therapeutics Committee meeting,
a direct thrombin inhibitor (DTI)
preprinted order form and dosing
protocol was approved. The purpose of form and protocol is to set
guidelines that ensure the appropriate use, dosing, and monitoring
of DTIs (ie, argatroban, bivalrudin) in the adult population.
This protocol excludes patients in
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Table 1. Dosing Recommendations for Erythropoiesis-stimulating Agents (ESAs)
FDA indications
and recommended
starting doses
**Please see package insert for additional information
regarding when to
increase/decrease
dose and maintenance dosing**

Black-Box
Warnings

Contraindications

Adverse Effects
(most common)

Monitoring/
Recommendations

Epoetin alfa (EPOGEN®/PROCRIT®)5,6

Darbopoetin alfa (ARANESP®)7

Anemia of Chronic Renal Failure
▪ Adults: 50 to 100 units/kg TIW
▪ Pediatrics: 50 units/kg TIW
Anemia in Cancer Patients Receiving Chemotherapy
▪ Adults: 150 units/kg SC TIW or 40,000 units SC weekly
▪ Pediatrics: 600 units/kg IV weekly
(maximum = 40,000 units)
Anemia in zidovudine-treated HIV patients (serum
erythropoietin concentrations < 500 mUnits/mL)
▪ 100 units/kg TIW IV or SC x 8 weeks
Reduction of Allogeneic Blood Transfusion in Surgery
Patients
▪ 300 units/kg/day SC for 10 days prior to surgery, on the
day of surgery, and for 4 days post-surgery
▪ Baseline Hgb should be >10 to <13 g/dL

Anemia of Chronic Renal Failure
▪ Adults: 0.45 micrograms /kg IV
or SC weekly
▪ Pediatrics: not studied
Anemia in Cancer Patients on Chemotherapy
▪ Adults: 2.25 micrograms/kg SC weekly or
500 micrograms SC once every 3 weeks
▪ Pediatrics: not studied

INCREASED MORTALITY, SERIOUS CARDIOVASCULAR AND THROMBOEMBOLIC EVENTS, AND
TUMOR PROGRESSION

Renal Failure:
▪ Patients experienced greater risks for death and serious cardiovascular events when administered
ESAs to target higher versus lower Hgb concentrations (13.5 vs. 11.3 g/dL; 14 vs. 10 g/dL) in
2 clinical studies.
▪ Individualize dosing to achieve and maintain Hgb concentrations within the range of 10 to 12 g/dL
Cancer:
▪ ESAs shortened overall survival and/or time-to-tumor progression in clinical studies in patients with
advanced breast, head and neck, lymphoid, and non-small cell lung malignancies when dosed to target a
Hgb of ≥ 12 g/dL.
▪ The risks of shortened survival and tumor progression have not been excluded when ESAs are dosed to
target a Hgb of < 12 g/dL.
▪ To minimize these risks, as well as the risk of serious cardio- and thrombovascular events, use the lowest dose needed to avoid red blood cell transfusions.
▪ Use only for treatment of anemia due to concomitant myelosuppressive chemotherapy.
▪ Discontinue following the completion of a chemotherapy course.
Perisurgery:
▪ Increased the rate of deep venous thromboses in patients not receiving prophylactic anticoagulation. Consider deep venous thrombosis prophylaxis.
▪ Uncontrolled hypertension
▪ Uncontrolled hypertension
▪ Known hypersensitivity to mammalian cell-derived
▪ Known hypersensitivity to active subproducts
stance or any of the excipients
▪ Known hypersensitivity to albumin
Hypertension
Clotted vascular access
Fatigue
Fever
Headache
Shortness of breath
Edema
Dyspnea
Tachycardia
Hyperkalemia
Nausea/vomiting Hypertension
Nausea/vomiting
Diarrhea
Diarrhea
Edema
Pyrexia

▪ Closely monitor and aggressively control blood pressure
▪ Decrease dose if Hgb increase exceeds 1 gm/dL in any 2-week period
▪ Monitor transferrin saturation and serum ferritin at baseline and during therapy
(Goal: transferrin > 20% and ferritin at least 100 ng/mL)
▪ Iron supplementation is recommended to maintain iron stores
▪ Frequent monitoring of Hgb/hematocrit, especially during initiation (twice weekly)

TIW: three times weekly; Hgb: hemoglobin; SC: subcutaneous; IV: intravenous
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FORMULARY UPDATE FOR OCTOBER 2007
The Pharmacy and Therapeutics
Committee recently approved the
actions listed below. The formulary effective date was November
15, 2007.
Additions:
Rosuvastatin (Crestor®) is an
HMG-CoA reductase inhibitor
similar to other medications
within this class. Rosuvastatin is
less than 10% metabolized by
CYP2C9 liver enzymes, but increased plasma concentrations
may be found in patients with severe renal impairment and/or hepatic disease. The adverse effects
associated with rosuvastatin are
similar to others within the class.
Serum cholesterol and liver function should be monitored on a
regular basis in patients receiving
rosuvastatin. Cost analysis shows
that rosuvastatin is less expensive
when compared with atorvastatin
directly.
5-, 10-, 20-, 40-mg tablets
Hepatitis B Immunoglobulin
(HepaGamB™) is indicated for
post-exposure to hepatitis B.
Compared to the current product
on formulary (Nabi-HB®), Hepa-

GamB™ has an additional indication for prevention of hepatitis
B recurrence following liver
transplantation. For this indication, HepaGamB™ should be
administered intravenously (IM
administration for both products
is indicated for post-exposure to
hepatitis B). HepaGamB™ is
formulated with maltose; therefore, diabetic patients should be
monitored closely for changes in
blood glucose. Additionally,
there is a cost-savings associated
with switching from Nabi-HB®
to HepaGamB™.
1-, 5-mL vials
Line Extensions:
Sodium bicarbonate 5%
[500-mL bottle]
Hydroxyzine hydrochloride
[25-mg/mL extemporaneous
solution]
Deletions:
Hepatitis B Immunoglobulin
(Nabi-HB®) [1, 5 mL vials]
Meperidine [50-mg tablet]
Amino-Cerv cream [77.9-g tube]

the Children’s Hospital and DTIs
ordered for other indications
(including cardiac catheterization).

pharmacist to manage DTI therapy without contacting the physician after the initial order is
placed.

Additionally, the protocol describes the role of a credentialed
pharmacist to make decisions in
dosage adjustments of the DTIs.
Within the preprinted form, the
physician will have the option of
choosing the “Pharmacy to Dose”
protocol. This protocol allows the

Based on new policy changes
(see page 7), pharmacy will also
be able to give verbal/telephone
orders to nurses without the physician’s cosignature. The nurse
will write the order with the credentialed pharmacists name and
specific “Pharmacy to Dose”.

Deletions (continued):
Ergocalciferol [500,000-IU/mL
intramuscular injection]
Quinine sulfate [260- and 325-mg
tablets and capsules]
Other Action Items:
All mixed insulin products will be
restricted from use and cannot be
ordered through the nonformulary
process. Additionally, patients are
prohibited from using their own
home supply. The products
affected include the following:
▪ NovoLIN® 70/30 (NPH/regular)
▪ NovoLOG® 70/30
(aspart protamine/aspart)
▪ HumuLIN® 70/30 (NPH/regular)
▪ HumalLOG® 75/25 Mix
(lispro protamine/lispro)
For patients admitted on a mixed
insulin product, separate orders
must be written for basal insulin
[insulin glargine (Lantus®) or
insulin NPH (Novolin® N)] and
prandial insulin [insulin aspart
(Novolog®)].
The Diabetes
Management Service has posted a
insulin conversion resource on the
clinical order form page to assist
with conversions.
The pharmacist will cosign the
order within 48 hours per policy.
The DTI program began this
month and will be piloted with 3
credentialed pharmacists. As more
pharmacists undergo the credentialing process, a list will be maintained online of the approved
pharmacists. The DTI program
provides 24-hr coverage for these
patients. There, if a physician selects the “Pharmacy to Dose” pro-
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FORMULARY UPDATE FOR NOVEMBER 2007
The Pharmacy and Therapeutics
Committee recently approved the
actions listed below. The formulary effective date was December
17, 2007.
Not Added:
Omeprazole/sodium bicarbonate
(Zegerid®) is formulated to prevent omeprazole from being degraded in the stomach prior to absorption. Other advantages include the antacid effect seen with
the sodium bicarbonate, faster onset of action, and higher omeprazole plasma concentrations. With
the acquisition cost for Zegerid®
being significantly higher than
other PPIs on formulary, the Committee felt that Zegerid could be
reserved for outpatient treatment.
Posaconazole (Noxafil®) was not
added to the formulary based on
similarities between posaconzaole
and formulary azole antifunals,
tocol, a credentialed pharmacist
will be paged to assess the patient.
A physician may choose not to
participate in the “Pharmacy to
Dose” DTI program, but must still
use the preprinted order form to
order DTIs.

Changes to Medication
Order Writing Policies
Updated Intravenous (IV) Push
Medication Administration
Policy and Charts
The purpose of the IV push medication policy (C-151) is to ensure
that medications administered to
patients via the IV push route are

limitations in dosage form and
administration, and cost.

▪ Valproic acid syrup
[250-mg/5-mL unit dose cups]

Line Extensions:
▪ Antihemophilic factor VIII
(Helixate®) injection
▪ Hydromorphone syrup
[1-mg/mL]
▪ Multiple vitamins liquid
(AquADEK®)
▪ Amphetamine/
dexamphetamine (Adderall
XR) [5-mg capsule]
▪ Aripiprazole (Abilify®) liquid
[1-mg/mL]
▪ Valproic acid syrup [500
mg /10-mL unit dose cups]

Other Action Items:
Direct Thrombin Inhibitor Policy
and Pharmacy Dosing Protocol
was approved to be piloted in
early 2008. The preprinted order
form creates a standardized format
for ordering argatroban and bivalrudin in patients with heparin induced thrombocytopenia (HIT).
(See story on page 7)

Deletions:
▪ Aprotinin (Trasylol®) injection
▪ Antihemophilic factor VIII
(Kogenate®) injection
▪ Multiple vitamins (ADEK®)
pediatric drops
▪ Japanese encephalitis vaccine
(JE-Vax®)
evaluated for safety from the
standpoint of the medication and
the health care professional administering the medication. The
published IV push charts serve
as the official guideline regarding IV push administration of
medications in all patients. The
charts define in which patient
care units and under what circumstances individual medications may be administered via IV
push. Some patient care units
have special monitoring capa-

Intravenous (IV) Push Medication
Administration Charts have been
updated for adult and pediatric
patients. The charts are posted on
the Formulary and Drug Information Resource Web page under
Medication Policies/Guidelines.
(See story on page 6)
Policy C78: Medication Orders.
has been updated to reflect
changes to the use of range orders
(See story below).
bilities or have nursing personnel
with specific credentials; thus, the
IV push administration of certain
medications may be allowed in
some patient care areas and prohibited in others. The direct links
are provided in Figure 2 and can
be found at the following locations:
▪ Formulary and Drug Information Resources Web page
▪ Nursing Tool Box under Pharmacy Links

Figure 2. Links for Adult and Pediatric IV Push Administration Charts
MUSC-MC Adult IV Push Medication Administration Chart :
www.musc.edu/pharmacyservices/forms-charts/ivpushadultcurrent.pdf.
MUSC Children’s Hospital IV Push Medication Administration Chart:
www.musc.edu/pharmacyservices/forms-charts/ivpushpedcurrent.pdf.
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If a medication is not listed on the
chart, the medication cannot be
given IV push, as the safety has
not been evaluated. Requests for
changes to the charts can be forwarded to the Drug Information
Center at 2-3896.
Revisions to Range Order Section
of Policy C78: Medication Orders
A range order can be defined as a
medication order in which the
dose of medication can vary depending on the patient’s status and
provider assessment, within a
specified time frame (ie, morphine
2 - 4 mg every 2 –3 hrs prn).
The Joint Commission states that
range orders should only be allowed if there are clear criteria
provided in the order. Guidelines
for dosing assures that the order
will be interpreted consistently
from staff member to staff member and that each practitioner has
a clear understanding of how the
patient will be treated.
The policy provides guidelines for
writing range orders, where if a
dosing range is used then the prescriber must include clear guidelines for dosing so that it can be
interpreted consistently among all
staff members. For the previous
morphine example, the order
should also include guidelines for
when to give 2 mg versus 4 mg
(ie, 2 mg for moderate pain; 4 mg
for severe pain),
Time interval ranges (ie, 2-4 hrs)
are not permitted. If ranged time
intervals are written, the shortest
time interval will be used in transcribing and acting upon the order. Therefore, the shortest time
interval will be placed on the
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MAR (eg, every 2-4 hours prn
will be placed on the MAR as
every 2 hours prn).

medications. These times should
be followed in all patients unless
there is a clinical justification for
deviating from the policy.

Standard Administration Times
Recently, the standardized administration times (SATs) were
changed so that the frequency of
BID is reflected in a 9 AM and
5 PM schedule (it was formerly
an 8 AM and 8 PM schedule).
This new time is consistent with
typical dosing in the outpatient
setting, where the patient should
take the medication twice a day
within waking hours.
There are some medications that
should be given using a 12 hour
interval. Therefore, the medication order should be written using either BID or Q12hr, depending on the medication. If a
medication should be given with
a 12-hr interval the order should
use Q12h.

“Pharmacy-to-Dose Protocols:”
Changes to Policy C56 and C78
With the approval of the direct
thrombin inhibitor (DTI)
“Pharmacy to Dose” protocol,
MUSC policy C78: Medication
Orders has been changed to include orders written by pharmacist
who are credentialed to participate
in the “Pharmacy to Dose” program. The wording “Pharmacy to
Dose” when specified in physician
orders will serve as a written
agreement between the prescriber
and the Department of Pharmacy
Services to authorize a credentialed pharmacist to initiate, modify or discontinue the specified
medication.

If the health care practitioner
acting upon an order written for
BID feels that there is a clinical
reason to have a 12-hr interval,
the change should be made.
Therefore, pharmacists entering
the order may change the BID to
a Q12 hr interval and nurses may
also request a change if the
medication requires Q12 hr interval.

Protocols eligible (eg, aminoglycosides, vancomycin, direct
thrombin inhibitors) for
“Pharmacy-to-Dose” will be reviewed and approved by the Pharmacy and Therapeutics Committee. The Department of Pharmacy
Services will ensure that competencies are maintained for credentialed pharmacists who are allowed to participate in Pharmacy
to Dose protocols.”

The approved SATs can be
found on the Formulary and
Drug Information Resources
web site under “Medication
Charts and Other Documents” or
at: www.musc.edu/pharmacyservices/
medusepol/SATimes.pdf. The SATs
are important to provide consistency across the organization for
dispensing and administering

In addition, MUSC policy C56:
Verbal Orders has been changed
to INCLUDE the “Pharmacy to
Dose” program where a credentialed pharmacist can give a nurse
a verbal/telephone order for DTI
management as ordered by the
prescriber on the preprinted form.
The order will be signed by the
pharmacist within 48 hours.

